{
  "pmid": "41459763",
  "title": "Therapeutic benefits of maintaining CDK4/6 inhibitors and incorporating CDK2 inhibitors beyond progression in breast cancer.",
  "abstract": "CDK4/6 inhibitors (CDK4/6i) with endocrine therapy are standard for hormone receptor-positive (HR",
  "disease": "breast cancer"
}